Surgical Management Strategy for Breast Cancer Patients During the COVID-19 Outbreak
Open Access
- 1 July 2020
- journal article
- editorial
- Published by Taylor & Francis Ltd in Cancer Management and Research
- Vol. ume 12, 6053-6058
- https://doi.org/10.2147/cmar.s258121
Abstract
In December 2019, a new coronavirus pneumonia began to break out globally. COVID-19 pandemic challenges the health systems worldwide and influences the treatments for other diseases. The incidence rate of breast cancer ranks first among all malignant tumors among women. During the pandemic, medical workers should strictly monitor the condition of patients and strengthen the management and prevention measures to make sure patients can be operated safely. This article will discuss the arrangements and management of surgical treatment for patients with breast cancer.Keywords
This publication has 33 references indexed in Scilit:
- Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical SuspicionRadiology, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, ChinaInternational Journal of Infectious Diseases, 2020
- Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other PhenotypesAnnals of Surgical Oncology, 2019
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2019
- Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)Chinese Journal of Cancer Research, 2019
- Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependentOncotarget, 2016